Souhaitez-vous accéder aux communiqués récents ?

The FDA’s second major labeling update in 16 months — after its February 2025 removal of the cardiovascular boxed warning — marks a historic modernization of how testosterone therapy is prescribed,...

RALEIGH, N.C., June 18, 2026 (GLOBE NEWSWIRE) -- New research from Marius Pharmaceuticals reveals significant gaps in men's health awareness and engagement, with 65% of U.S. men ages 40-65 reporting...

RALEIGH, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc., the makers of KYZATREX® (testosterone undecanoate) CIII Capsules, today announced a significant expansion of its...

RALEIGH, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced the company will initiate a new post-marketing clinical study for potential label expansion evaluating...

RALEIGH, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced that its Chief Executive Officer, Shalin Shah, will speak at the FDA Expert Panel on Testosterone...

RALEIGH, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. a patient-centric healthcare company committed to advancing innovative therapies for testosterone deficiency, today...

RALEIGH, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc., today announced the formation of an all-female advisory board to advance the company’s efforts in addressing the...

RALEIGH, N.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced a collaboration with Hims & Hers™, one of the largest digital health platforms for men, to make...

RALEIGH, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, announced today that the...

RALEIGH, N.C., April 22, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, announces its partnership...